Precision Medicine in Oncology

Broad Testing for Multiple Genes Benefits Patients With Cancer, Relatives

October 30th 2020, 9:45pm


Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.

Foundation Medicine Notches Additional FDA Approvals

October 29th 2020, 11:30pm


The FDA has approved new indications for Foundation Medicine's liquid biopsy assay and also its tissue-based companion diagnostic for solid tumors.

Cancers of Unknown Primary Site May Benefit From NGS Profiling

October 23rd 2020, 6:45pm


The study describes how RNA sequencing and DNA sequencing for selected genes were performed simultaneously to evaluate gene expression and alterations in order to predict tumor origin.

OneOncology Launches Research Network Subsidiary

October 19th 2020, 10:00am


The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.

Australian Researchers Illustrate Use of ctDNA in Metastatic Breast Cancer

October 17th 2020, 8:00pm


A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.

Germline Genetic Testing After Tumor-Only Sequencing Finds Additional Targets, Study Says

October 9th 2020, 5:30pm


The researchers, from a medical genetics firm, said the findings illustrate the usefulness of germline analysis for the right patient.

Dr Blythe Adamson: Checkpoint Inhibitor Approval Linked to Uptick in Systemic End-of-Life Care

October 8th 2020, 2:00pm


Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care

Canadian Study Explores Use of Liquid Biopsies in Advanced NSCLC

October 3rd 2020, 5:00pm


Next-generation sequencing (NGS) of cell-free DNA (cfDNA) may improve diagnostic testing in advanced lung cancer.

Dr Andre Goy Discusses What We’ve Learned About CAR T Therapies and Cytokine Responses

October 1st 2020, 6:00pm


Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

Dr David Debono Previews Precision Health, Value-Based Care Discussion at PCOC® 2020

September 21st 2020, 8:37pm


The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.